Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Last updated: November 9, 2022
Sponsor: Janssen Research & Development, LLC
Overall Status: Planned

Phase

N/A

Condition

Multiple Myeloma

Leukemia

Lymphoproliferative Disorders

Treatment

N/A

Clinical Study ID

NCT05463939
CR109154
64007957MMY4001
  • Ages > 18
  • All Genders

Study Summary

The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient diagnosed with Relapsed or Refractory Multiple Myeloma

  • Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial

Study Design

Study Start date:
Estimated Completion Date:

Connect with a study center

  • DUMMY

    Dummy, 99999
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.